Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening. ASCO 2026 highlights breast cancer care: gene tests ...

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...

CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...

A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Objective responses occurred across FRα strata, with ORR 40% in 0%–24% FRα expression and 54% in ≥75%, suggesting limited dependence on high IHC expression. Clinical activity persisted in heavily ...

Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...